Featured Publications

IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P252,
Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer

Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P240
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery

Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104

Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P254
Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine

Publications

Found 11 Results
Page 1 of 2

Reporting guidelines for human microbiome research: the STORMS checklist

The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…

Journal: Nature Medicine


Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA

Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…

Journal: Cell Reports


Orchestrating and sharing large multimodal data for transparent and reproducible research

Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by independent research groups, regardless of its validity. It is therefore crucial…

Journal: Nature Communications


A primer on applying AI synergistically with domain expertise to oncology

Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model it has created a promising environment for revolutionizing cancer diagnosis, treatment,…

Journal: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer


A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having…

Journal: Genome Biology


Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence…

Journal: Genome Biology


Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…

Journal: Nature Biotechnology


Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery

The tremendous expansion of data analytics and public and private big datasets presents an important opportunity for pre-clinical drug discovery and development. In the field of life sciences, the growth…

Journal: Biochemical Pharmacology


The international MAQC Society launches to enhance reproducibility of high-throughput technologies

Reproducibility is a fundamental hallmark of good science. The US Food and Drug Administration (FDA)-led Microarray and Sequencing Quality Control (MAQC/SEQC) consortia conducted three projects 1,2,3 to assess the reliability and…

Journal: Nature Biotechnology 


A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients…

Journal: Genome Medicine


Page 1 of 2